Novan, Inc.

Novan, Inc.

$0.09
-0.03 (-24.84%)
NASDAQ Capital Market
USD, US
Biotechnology

NOVN Price Chart

Basic
Market Cap$2.64M
Price$0.09
52 Week Range0.082-3.33
Beta-0.04
Margins
Gross Profit Margin68.74%
Operating Profit Margin-149.90%
Net Profit Margin-82.85%
Valuation (TTM)
P/E Ratio-0.11
Price to Sales Ratio0.11
Price to Book Ratio0.45
PEG Ratio-0.00

Industry

Biotechnology

Sector

Healthcare

Full-Time Employees

90

IPO Date

2016-09-21T00:00:00.000Z

Description

Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Phone

919 485 8080

Address

4020 Stirrup Creek Drive, Durham, CA, 27703, US

CIK

0001467154